NRx Pharmaceuticals (NASDAQ:NRXP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
NRx Pharmaceuticals (NASDAQ:NRXP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion [Yahoo! Finance]
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.